Houston Methodist Cancer Center names Dr. Daniela Matei as next director

She is also the leader of the Translational Research in Malignancies Program at the Robert H. Lurie Comprehensive Cancer Center and has served on various committees, including:

• National Cancer Institute
• American Society of Clinical Oncology
• Ovarian Cancer NCI Taskforce
• Gynecologic Oncology Group (now NRG Oncology)
• National Comprehensive Cancer Network

“We could not be more excited to welcome Dr. Matei to lead the Neal Cancer Center,” said Marc L. Boom, president and CEO of Houston Methodist, in the release. “Her expertise will play a key role in advancing translational and precision cancer research at Houston Methodist, and her leadership will have far-reaching benefits for cancer patients, researchers and trainees in our city, across Texas and internationally.”

Matei has contributed to ovarian cancer biology and therapeutics, leading several trials in women with gynecologic cancer and publishing more than 170 papers, with over 15,000 citations, according to the release.

What they’re saying

Chang said Matei’s vision will “enhance the momentum of our research enterprise and support our shared goal of turning scientific innovation into real-world impact for patients.”

“Dr. Matei is an exceptional clinical scientist in ovarian cancer resistance mechanisms, with expertise in translating basic discoveries into clinical trials,” Chang said in the release. “Her arrival reflects the strength of our academic and research mission and our commitment to discoveries that move swiftly into practice.”

What’s next?

Matei will begin her role as director in April, per the release.